| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ... Leukemia 33 (1), 159-170, 2019 | 406 | 2019 |
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ... Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018 | 406 | 2018 |
| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 350 | 2017 |
| Bridger: a new framework for de novo transcriptome assembly using RNA-seq data Z Chang, G Li, J Liu, Y Zhang, C Ashby, D Liu, CL Cramer, X Huang Genome biology 16, 1-10, 2015 | 325 | 2015 |
| Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ... Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016 | 216 | 2016 |
| Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma L Rasche, D Alapat, M Kumar, G Gershner, J McDonald, CP Wardell, ... Leukemia 33 (7), 1713-1722, 2019 | 135 | 2019 |
| Revealing the impact of structural variants in multiple myeloma EH Rustad, VD Yellapantula, D Glodzik, KH Maclachlan, B Diamond, ... Blood cancer discovery 1 (3), 258-273, 2020 | 90 | 2020 |
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated … JR Jones, N Weinhold, C Ashby, BA Walker, C Wardell, C Pawlyn, ... Haematologica 104 (7), 1440, 2019 | 83 | 2019 |
| The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma S Thanendrarajan, E Tian, P Qu, P Mathur, C Schinke, F van Rhee, ... Haematologica 102 (9), e364, 2017 | 80 | 2017 |
| The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma EM Boyle, S Deshpande, R Tytarenko, C Ashby, Y Wang, MA Bauer, ... Nature communications 12 (1), 293, 2021 | 76 | 2021 |
| Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker SS Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, CK Stein, ... Blood cancer journal 7 (2), e535-e535, 2017 | 71 | 2017 |
| Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma A Mikulasova, C Ashby, RG Tytarenko, P Qu, A Rosenthal, JA Dent, ... Haematologica 105 (4), 1055, 2020 | 52 | 2020 |
| BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma EM Boyle, C Ashby, RG Tytarenko, S Deshpande, H Wang, Y Wang, ... Clinical Cancer Research 26 (10), 2422-2432, 2020 | 46 | 2020 |
| Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? C Pawlyn, A Loehr, C Ashby, R Tytarenko, S Deshpande, J Sun, ... Leukemia 32 (7), 1561-1566, 2018 | 44 | 2018 |
| Accelerated single cell seeding in relapsed multiple myeloma HJ Landau, V Yellapantula, BT Diamond, EH Rustad, KH Maclachlan, ... Nature communications 11 (1), 3617, 2020 | 43 | 2020 |
| Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials SA Danziger, M McConnell, J Gockley, MH Young, A Rosenthal, ... PLoS Medicine 17 (11), e1003323, 2020 | 40 | 2020 |
| Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns C Schinke, EM Boyle, C Ashby, Y Wang, V Lyzogubov, C Wardell, P Qu, ... Blood cancer journal 10 (6), 70, 2020 | 33 | 2020 |
| The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states L Rasche, C Schinke, F Maura, MA Bauer, C Ashby, S Deshpande, ... Nature Communications 13 (1), 4517, 2022 | 25 | 2022 |
| Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA S Deshpande, RG Tytarenko, Y Wang, EM Boyle, C Ashby, CD Schinke, ... European Journal of Haematology 106 (2), 230-240, 2021 | 25 | 2021 |
| Chromothripsis as a pathogenic driver of multiple myeloma F Maura, EM Boyle, EH Rustad, C Ashby, D Kaminetzky, B Bruno, ... Seminars in cell & developmental biology 123, 115-123, 2022 | 24 | 2022 |
Christopher WardellAssistant Professor of Bioinformatics, University of Arkansas for Medical SciencesVerified email at uams.edu
